Share This Page
Drugs in ATC Class N07X
✉ Email this page to a colleague
Subclasses in ATC: N07X - OTHER NERVOUS SYSTEM DRUGS
N07X Market Analysis and Financial Projection
The ATC Class N07X (Other Nervous System Drugs) encompasses a diverse range of therapies for conditions not classified under standard CNS categories, including treatments for Alzheimer’s disease, Tardive Dyskinesia, and rare neurological disorders. Here’s an analysis of its market dynamics and patent landscape:
Market Dynamics
-
Growth Trends
- The global CNS therapeutics market is projected to grow from $110.4 billion in 2022 to $238.8 billion by 2032, driven by rising neurodegenerative and psychiatric disorders[7][14].
- N07X-specific therapies such as Valbenazine (Ingrezza®, for Tardive Dyskinesia) and AL 002 (anti-TREM2 monoclonal antibody for Alzheimer’s) are key contributors. Sales of Valbenazine reached $53.3 million in Belgium/Luxembourg alone in 2020[5], reflecting strong demand.
-
Key Drivers
- Aging Populations: Alzheimer’s and Parkinson’s diseases are major growth drivers. Over 50 million people globally have dementia[14].
- Innovative Therapies: Biologics (e.g., monoclonal antibodies) and gene therapies (e.g., Zolgensma® for spinal muscular atrophy) are reshaping the market[3][9].
- Regulatory Support: Expedited approvals for novel mechanisms like TREM2-targeted drugs (AL 002)[2].
-
Regional Insights
- North America dominates (39.5% revenue share in 2024) due to advanced healthcare infrastructure and high R&D investments[14].
- Asia-Pacific is the fastest-growing region (11.1% CAGR) due to increasing healthcare access and aging demographics[14].
-
Challenges
- Patent Expirations: Loss of exclusivity for blockbusters like Vyvanse® (2023) and Gilenya® (post-2024) will boost generics[3][13].
- High Development Costs: CNS drug trials face high failure rates, with only 8.2% approval success[14].
Patent Landscape
-
Key Drugs and Patents
- AL 002 (Alector): Seven patent families protect its TREM2-targeted mechanism, with expirations staggered between 2035–2042[2]. Phase II trials are ongoing in the U.S., EU, and Australia[2].
- Valbenazine (Ingrezza®): First approved TD treatment (2017)[8]. Its ATC classification (N07XX13) falls under N07X, but patent details are less clear from available data.
-
Patent Strategies
- White Space Identification: Tools like CPC code analysis and forward/backward citation mapping help identify innovation gaps[17].
- High-Value Patents: CRISPR/Cas9 and gene-editing technologies dominate filings for CNS therapies (e.g., allogeneic CAR-T patents)[4].
-
Competitive Landscape
- Top Players: Biogen, Roche, and Novartis lead CNS innovation[3][14]. Alector and Acadia Pharmaceuticals are emerging in niche segments like Alzheimer’s[2][9].
- Generics Impact: Post-2030, Ozempic® generics may indirectly affect N07X by increasing off-label use for weight loss, complicating market dynamics[10].
Future Outlook
- Revenue Forecast: The N07X segment is poised for growth, with the broader CNS market expected to hit $431 billion by 2035[9].
- Innovation Focus: Companies are prioritizing biologics, neuroprotective agents, and blood-brain barrier-penetrating technologies (e.g., AbbVie’s ALIA-1758)[9].
- Regulatory Risks: Stricter cost-containment policies in Europe may delay market entry for premium-priced therapies[13].
Key Developments
| Drug | Indication | Status | Patent Expiry |
|---|---|---|---|
| AL 002 | Alzheimer’s Disease | Phase II Trials | 2035–2042[2] |
| Valbenazine | Tardive Dyskinesia | Marketed | Not Disclosed |
| Ozempic® | Off-label CNS uses | Litigation | 2031–2033[10] |
The N07X market reflects a blend of innovation and volatility, driven by unmet medical needs and evolving IP strategies. While biologics and gene therapies offer long-term growth, generics and regulatory hurdles will shape competitive dynamics post-2030.
References
- https://www.marketsandmarkets.com/Market-Reports/air-traffic-control-equipment-market-159216929.html
- https://adisinsight.springer.com/drugs/800052598?bpIds=3000093925%2C3000118986&checksum=9e1113474fbf388e7d91fac2b4e806c9886722d8-1554955266899-e64758e7d97d86c4ccc012ea87b8b7e2979854bdf911905893237a83e0d9ad4a4dd87f752524ca51b15f3911efa7a85e
- https://www.ihealthcareanalyst.com/global-central-nervous-system-therapeutics-market/
- https://www.globenewswire.com/news-release/2025/03/13/3042364/0/en/Allogeneic-CAR-T-Cell-Patent-Landscape-and-Forecast-Report-2024-2032-Profiles-of-Artiva-Biotherapeutics-Poseida-Therapeutics-Nanjing-Beiheng-Biological-Technology-NantCell-GC-Cell-.html
- https://www.iqvia.com/-/media/iqvia/pdfs/belgium/sales-trends/2020/may-belgian-reg-med-best.pdf
- https://sante.gouv.fr/IMG/pdf/Rapport_d_activite_du_CEPS_en_2004_version_anglaise.pdf
- https://www.gminsights.com/industry-analysis/central-nervous-system-therapeutics-market
- https://pubchem.ncbi.nlm.nih.gov/compound/INGREZZA
- https://www.globenewswire.com/news-release/2025/01/08/3006421/28124/en/Central-Nervous-System-CNS-Therapeutics-Market-Forecast-2025-2035-by-Disease-Drug-Class-Distribution-Channel-and-Region.html
- https://www.markmanadvisors.com/blog/2025/2/7/what-is-the-patent-landscape-for-novo-nordisks-semaglutide-products-ozempic-wegovy-and-rybelsus
- https://www.businesswire.com/news/home/20250314223814/en/Mexico-Gift-Card-Market-Report-2025-Strong-Growth-Projected-with-Evolving-Consumer-Preferences-and-Tech-Integration---Forecast-to-2029---ResearchAndMarkets.com
- https://patents.google.com/patent/US8058291B2/en
- https://health.ec.europa.eu/system/files/2016-11/creativ_ceutical_eu_pharmaceutical_expenditure_forecast_0.pdf
- https://www.grandviewresearch.com/industry-analysis/central-nervous-system-cns-therapeutic-market
- https://www.us.jll.com/en/trends-and-insights/research/global/global-real-estate-outlook
- https://atcddd.fhi.no/atc_ddd_index/?code=N07XX25
- https://www.ipcheckups.com/patent-landscape-analysis-overview/
- https://www.hmr.co.com/wp-content/uploads/2022/11/Market-Watch-Ireland-October-2022.pdf
- https://www.mdpi.com/1660-4601/17/1/200
More… ↓
